article thumbnail

Imugene HER2 vaccine hits target in stomach cancer trial

pharmaphorum

A peptide vaccine developed by Australia’s Imugene has reduced tumour size in around half of patients with HER2-positive gastric or gastroesophageal junction (GEJ) cancer in a phase 2 trial. The post Imugene HER2 vaccine hits target in stomach cancer trial appeared first on.

Vaccines 119
article thumbnail

Novel vaccine delivers significant survival in lung cancer trial

European Pharmaceutical Review

A T-cell epitope cancer vaccine significantly improved overall survival in non-small cell lung cancer (NSCLC) compared to chemotherapy, Phase III data published in Annals of Oncology has shown. percent with chemotherapy. The cancer vaccine offered an overall survival of 11.1 months for chemotherapy.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Opinion: A challenge trial can streamline testing of hepatitis C vaccines

STAT

Chemotherapy can save people from cancer, but the side effects can wreak havoc on their bodies for months or years. Trade-offs in medicine can be harsh, even when clearly necessary. These trade-offs aren’t limited to the clinical world. They are also part of research.

article thumbnail

Could personalised mRNA vaccine be first for cancer?

European Pharmaceutical Review

A BioNTech-led Phase I trial demonstrated preliminary evidence that adjuvant autogene cevumeran, a personalised mRNA neoantigen vaccine, in combination with atezolizumab (Genentech) and mFOLFIRINOX can induce substantial T cell activity in pancreatic ductal adenocarcinoma (PDAC). Can an mRNA vaccine stimulate T cell response?

article thumbnail

What side effects to expect from the shingles vaccine

The Checkup by Singlecare

Luckily, there’s a shot to help prevent it: Shingrix, the shingles vaccine. The Shingrix vaccine triggers the immune system to respond to the varicella virus and suppress the outbreak of shingles,” says David Cutler , MD, a family medicine physician at Providence Saint John’s Health Center in Santa Monica, California.

Vaccines 105
article thumbnail

Vaccine demonstrates benefit in delaying cancer relapse

European Pharmaceutical Review

A lymph node-targeted cancer vaccine has shown potential to prevent relapse of KRAS-mutated pancreatic and colorectal cancers in patients who have had surgery, according to a Phase I trial led by US researchers. Patients were given no more than 10 doses of the ELI-002 cancer vaccine targeted toward KRAS G12D and G12R mutations. “It

article thumbnail

Integrating personalised colorectal cancer vaccines into the evolving treatment landscape

Hospital Pharmacy Europe

The idea of cancer vaccines is not new, but Dr Victoria Kunene, consultant medical oncologist at Queen Elizabeth Hospital Birmingham, UK, is leading the charge in their latest iteration: personalised preventative and therapeutic mRNA vaccines against colorectal cancer.